Hauppauge, New York--(Newsfile Corp. - October 22, 2020) - COVAXX, a U.S. company developing a synthetic multitope peptide-based vaccine to fight COVID-19, today announced a global logistics partnership with Maersk, one of the world's largest shipping and integrated logistics providers. The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX's vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed.
To view the full announcement, including downloadable images, bios, and more, click here.
Goal is to bring a much needed COVID-19 vaccine to emerging and developing nations
Agreement establishes integrated logistics to enable efficient worldwide distribution of COVAXX's COVID-19 vaccine
Aim is to distribute up to a billion doses of the COVAXX synthetic vaccine worldwide in 2021
About Maersk. A.P. Moller - Maersk is an integrated container logistics company, connecting and simplifying trade to help our customers grow and thrive. With a dedicated team of over 80,000, operating in 130 countries we go all the way to enable global trade for a growing world. For more information, visit www.maersk.com. About COVAXX. The mission of COVAXX is to democratize health and safeguard lives around the world by tackling the global COVID-19 pandemic using cost-effective, scalable and proven science-based solutions. COVAXX is developing a multitope peptide-based vaccine for COVID-19, which has shown promising preclinical safety and efficacy data and is based on a commercially proven, scalable vaccine platform. COVAXX is a subsidiary of United Biomedical Inc (UBI), founded in 1985 and headquartered in New York. UBI has established a long legacy as a scientific trailblazer creating technological firsts, including the manufacture and commercialization of more than 100 million antibody blood diagnostic tests and 5 billion vaccine doses against infectious diseases in animal health. With exclusive access to UBI's core technology platforms, COVAXX can develop and commercialize high precision antibody tests and a promising COVID-19 vaccine that together would form a unique Differentiating Infected from Vaccinated Individuals (DIVI) system. For more information, visit www.covaxx.com and follow us on social media (Twitter - @COVAXX, Facebook - @COVAXX, LinkedIn - COVAXX and Instagram - @covaxxvaxxine).
Diane Murphy (310) 658.8756 email@example.com
David Schull (858) 717-2310 David.Schull@russopartnersllc.com
Thomas Boyd (704) 430 3442 firstname.lastname@example.org